
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc's positive outlook is supported by a 140% growth in Hepzato procedure volume in 2025, indicating increased utilization and commercial adoption by physicians. The company's year-end cash balance increased to $91.0 million, demonstrating operational efficiency and financial stability, which bodes well for future expansion efforts. Furthermore, management's focus on salesforce expansion, along with strong clinical data from the FOCUS trial, is anticipated to drive referral growth and treatment adoption in both existing and new markets.
Bears say
Delcath Systems Inc has recently lowered its full-year revenue expectations to $83M-$85M, down from a prior estimate of $93M-$96M, primarily due to a significant slowdown in new site activations and a decline in average revenue per kit linked to the Medicaid National Drug Rebate Agreement Program. The company faced unexpected summer seasonality and increased competition in clinical trials, leading to a dramatic decrease in new patient starts, which fell by approximately two-thirds per site as a result of scheduling challenges and appointment cancellations. Additionally, the company operates on a cash flow negative basis, raising concerns about its ability to sustain operations and generate forecasted revenues moving forward.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares